Absolutely. Right now the ecosystem of research drugs is large, easy to access and completely unregulated. And there is a huge incentive mechanism because you

Absolutely. Right now the ecosystem of research drugs is large, easy to access and completely unregulated. And there is a huge incentive mechanism because you could be the one to find the next EPO and thus have a major advantage over your competitors. Of course the problem is that the risk of issues is significantly higher because they simply aren't tested especially longitudinally.